We recently reprinted the bleeding disorders product catalog which has been distributed widely to treatment centers and chapters across the country. We have gotten some nice compliments on how the catalog is laid out and received some excellent feedback on how to improve it by being more consistent in referencing different products. I bring this up because we have additional copies of the catalog which we would like to get rid of before it becomes obsolete – please contact me if you would like more.

The product catalog will be obsolete soon enough because If I’m counting correctly, there are approximately 27 new products in the pipeline, including: 6 hemophilia A gene therapy products, 7 hemophilia B gene therapy products, 3 tissue factor pathway inhibitor (TFPI) products, 1 RNA interference product, 3 protein C or S inhibitor product, 2 subcutaneous, 2 additional EHL RFVIII, 1 implantable matrix, 1 EHL RFVIII which will start shipping in early 2020 and potentially a FVIIa which maybe here next year as well. There may be even more that I’m missing.

It is hard to really appreciate how remarkable the breadth, depth and speed of these developments are coming to our little community. The changes are transformative and of course, these improvements are as welcome as they are overwhelming. The decision tree for how to decide the most appropriate therapy for each patient is and will becoming even more daunting. The ATHN DATA Summit featured 15 posters all focused on assuring and/or documenting that the best outcomes for patients are found at federally-supported comprehensive hemophilia treatment centers, sometimes known as bleeding and thrombosis centers. There are also presently 10 active research studies being conducted by the HTC network to determine how to further improve outcomes for patients.

Ironically all of these advancements could seriously undermine the comprehensive care model that has made them possible. The comprehensive care model aggregated patients for clinical trials and focused the unique clinical talents of dedicated healthcare professionals. These new therapies will require the ongoing clinical care team that have made all of this possible, while changing the economics of how centers are able to fund this clinical care.

The Alliance is hard at work to understand the impact of these new treatments on HTCs and is working to develop reimbursement models that will support and strengthen the HTC network. As you know, the Hemophilia Alliance works to ensure member Hemophilia Treatment Centers have the expertise, resources and public support to sustain their integrated clinical and pharmacy services for individuals with bleeding and clotting disorders. Our mission – and yours – remains the same even with these advancements.

Team Alliance Contact Information

We work for you! Please don’t hesitate to contact any of us with any questions or concerns: